NDAVAGINALCREAM
Approved
Sep 1945
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 3d ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
SULTRIN is a vaginal cream containing a fixed combination of three sulfonamide antibiotics (sulfabenzamide, sulfacetamide, and sulfathiazole) approved in 1945. It is indicated for vaginal bacterial infections and vulvovaginitis. The triple sulfa formulation provides broad-spectrum antimicrobial coverage targeting common vaginal pathogens.
LOE Approaching
Product approaching loss of exclusivity with moderate competitive pressure (30% intensity) suggests defensive positioning and potential headcount optimization in coming years.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
SULTRIN offers minimal career advancement opportunity due to its mature lifecycle and approaching loss of exclusivity. Roles on this brand are typically focused on maximizing remaining patent life and defending against generic erosion rather than innovation or growth.
Brand ManagerField Sales Representative
Worked on SULTRIN at Johnson & Johnson? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.